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Abstract 
Cellular distribution and dynamics of mitochondria are regulated by several motor 
proteins and a microtubule network. In neurons, mitochondrial trafficking is crucial 
because of high energy needs and calcium ion buffering along axons to synapses during 
neurotransmission. The trafficking kinesin proteins (TRAKs) are well characterized for 
their role in lysosomal and mitochondrial trafficking in cells, especially neurons. Using 
whole exome sequencing, we identified homozygous truncating variants in TRAK1 
(NM_001042646:c.287-2A>C), in six lethal encephalopathic patients from three 
unrelated families. The pathogenic variant results in aberrant splicing and significantly 
reduced gene expression at the RNA and protein levels. In comparison with normal 
cells, TRAK1 deficient fibroblasts showed irregular mitochondrial distribution, altered 
mitochondrial motility, reduced mitochondrial membrane potential, and diminished 
mitochondrial respiration. This study confirms the role of TRAK1 in mitochondrial 
dynamics and constitutes the first report of this gene in association with a severe 
neurodevelopmental disorder. 
 
Abbreviated summary 
Several motor proteins regulate subcellular organelle distribution and dynamics. Ortal 
et al. report the first individuals who had fatal encephalopathy with pathogenic 
TRAK1 variants. Patients’ fibroblasts showed abnormal uncoupled respiration due to 
aberrant mitochondrial movement and distribution. This study provides new 
understanding of how mitochondrial dynamics relate to human disease.   
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Introduction 
The ability to move within cells is crucial for mitochondria to execute many cellular 
functions, including buffering of calcium ions, regulation of apoptosis and, most 
importantly, energy generation in the form of ATP. Of all cell types, neurons are 
particularly sensitive to any impairment in active mitochondrial transport along their 
axons and dendrites, since they must reach the distant synapses in response to changing 
requirements for energy and calcium buffering (Cai, Davis et al. 2011, Schwarz 2013). 
In the past two decades, numerous studies have demonstrated mitochondrial movement 
in neurons (Strom, Gal et al. 2008, Barnhart 2016), both in kinesin-mediated 
anterograde (Wang and Schwarz 2009) and dynein-mediated retrograde directions 
(Pilling, Horiuchi et al. 2006), using the microtubule network and protein complexes 
that enable their trafficking. Drosophila models of synaptic insufficiency identified 
Mitochondrial Rho GTPase (Miro) and Trafficking protein kinesin binding 1 
(TRAK1)/Milton as important for mitochondrial axonal transport (Stowers, Megeath et 
al. 2002, Guo, Macleod et al. 2005). Other elements of the transport machinery have 
been demonstrated to interact with TRAK1 and Miro1, including the mitochondrial 
calcium uniporter (MCU) complex, which regulates the influx of calcium into the 
mitochondrial matrix (Niescier, Chang et al. 2013), and Disrupted-In-Schizophrenia 1 
(DISC1), hypothesized to contribute to increased risk of psychiatric illness (Ogawa, 
Malavasi et al. 2014). 
Of the numerous proteins involved, the endogenous mammalian TRAK proteins, 
TRAK1 and TRAK2, were found to function as kinesin adaptors linking kinesin heavy 
chain (KHC) to mitochondria. Using both gene silencing (shRNAi) and dominant 
negative methodologies, Brickley and Stephenson showed that inhibiting the formation 
or the availability of the TRAK kinesin adaptor in axons of hippocampal pyramidal 
neurons caused a decrease in mitochondrial mobility (Brickley and Stephenson 2011). 
Specific knockdown of TRAK1, and not TRAK2, impaired mitochondrial mobility in 
neurons, whereas reconstitution of either one rescued TRAK1 shRNAi-induced arrest 
of mobility. 
Further studies elucidating the specific roles of TRAK1 and TRAK2 in mitochondrial 
trafficking showed that TRAK1 binds to both kinesin-1 and dynein/dynactin, is needed 
for normal axon outgrowth, and is primarily localized in axons. TRAK2, on the other 
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hand, predominantly interacts with dynein/dynactin, serves a role in dendritic 
development, and is preferentially localized in dendrites (van Spronsen, Mikhaylova et 
al. 2013). 
Impairment of mitochondrial transport or dynamics as a whole has been previously 
linked to several neurodegenerative disorders, including Parkinson’s, Alzheimer’s and 
Huntington’s diseases (Waterham, Koster et al. 2007, Mattson, Gleichmann et al. 2008, 
Schon and Przedborski 2011). However, thus far, disruption of the TRAK1-mediated  
mitochondrial trafficking has yet to be associated with a specific human disease. We 
now report six such cases from three unrelated families of similar origin. 
Materials and Methods 
Patients 
Patients were managed at the Metabolic Disease Unit and the Pediatric Neurology Unit 
at the Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-
Hashomer. Patients were enrolled in the clinical protocol 76-HG-0238, “Diagnosis and 
treatment of patients with inborn errors of metabolism and other genetic 
disorders”(identifier: NCT00369421), approved by the NHGRI IRB.  All parents of the 
patients gave written, informed consent. 
Whole exome sequencing  
Whole exome sequencing of affected individuals A.IV.3 and A.IV.8 (family A) and 
one parent (III.2) was performed using an Illumina TruSeq Exome capture kit and the 
HiSeq 2500 sequencing platform (Illumina, Inc,, San Diego, CA). Reads were aligned 
with human reference genome (hg19; NCBI build 37; Feb. 2009) using Burrows-
Wheeler transform (Li and Durbin 2009). Variant calling was performed with GATK 
(McKenna, Hanna et al. 2010) and functionally annotated using KGG-seq (Li, Gui et 
al. 2012). Given the consanguinity in the pedigree, homozygous variants were filtered 
based on allele frequency less than 0.01 with no reported healthy homozygotes in online 
databases, dbSNP, 1000G, ESP6500 and ExAC.  Likely pathogenicity was assessed if 
the variant was truncating (splicing or non-sense) or missense; in-frame indels were 
considered if they were predicted to be pathogenic by online prediction tools, 
PolyPhen2, SIFT, CADD and Mutation Taster. Confirmation and family screening of 
 6 
identified candidates were performed using direct Sanger sequencing (Applied 
Biosystems). 
 
Cell culture, RT-PCR, Quantitative PCR and Western blotting 
Dermal fibroblasts derived from affected patients were cultured in DMEM 
supplemented with 15% FBS, non-essential amino acid medium and pencillin-
streptomycin as described (Malicdan, Vilboux et al. 2015). Normal adult and neonatal 
dermal fibroblasts (ATCC PCS-201-012 and PCS-201-010) were purchased for control 
experiments. Total RNA was isolated from control and patients using RNeasy Mini Kit 
(Qiagen) and treated with DNase (Ambion, Life Technologies) and transcribed to 
cDNA as described (Malicdan, Vilboux et al. 2015) using high capacity RNA to cDNA 
kit (Applied Biosystems). In order to check the splice defect, primers binding to 
flanking exons (primer sequences are available upon request) were used to amplify the 
region of interest; PCR products were loaded onto a 3% agarose gel and the excised 
bands were sequenced. Quantitative real time PCR was performed using specific 
primers (primer sequences available upon request) with Power SYBR Green master 
mix (Applied Biosystems), and ran through a Bio-Rad qPCR machine (CFX96 Touch 
Real Time PCR detection system, Philadelphia, PA, USA) with standard qPCR 
parameters to analyze the expression of TRAK1 compared with the control gene 
POLR2A. We used different sets of primers to check the effect of the pathogenic variant 
on the expression of two predominant transcripts expressed in fibroblasts 
(NM_001042646.2 or Transcript 1 and NM_014965.4 or Transcript 2). Ct values were 
analyzed with the comparative CT method (Livak and Schmittgen 2001). The PCR 
products of the real time reactions were loaded into 2% agarose gel in order to compare 
the band intensity with qPCR results. For western blotting, total cell lysates were 
prepared from fully confluent T-75 culture flasks. Cells were lysed using  RIPA buffer 
(50 mM Tris, pH 7; 150 mM NaCl; 0.1% SDS; 0.5% sodium deoxycholate; 1% Triton 
x-100; and 1 mM EDTA) supplemented with protease inhibitors (complete, Mini, 
EDTA-free, Roche). Samples were quantified, electrophoresed on 4-12% Tris-Glycine 
gel and blotted onto nitrocellulose membrane through dry transfer (iBLOT, Invitrogen). 
Membranes were blocked with Li-Cor blocking buffer (Li-Cor Biosciences, Lincoln, 
NE, USA) for one hour, and then incubated with rabbit anti-TRAK1 antibody 
(HPA005853, Sigma, St Louis, MO, USA) and mouse anti-β-actin (Sigma). After 
 7 
several washes in PBS with 0.1% Tween, membranes were incubated with the 
appropriate secondary antibodies (Li-Cor Biosciences) and imaged under the Li-Cor 
imaging system (Li-Cor Biosciences). 
Electron Microscopy 
For electron microscopy, the specimens were fixed in 2.5% glutaraldehyde in 0.1M 
buffered cacodylate, post-fixed in 1% osmium tetroxide for one hour, dehydrated in a 
series of increasing ethanol concentrations, and finally embedded in epoxy resin - Agar 
mix (Agar Scientific LTD, Essex, UK) for 2 days at 60oC. Semi-thin sections were 
prepared from the blocks, and relevant areas were selected for ultra-thin sections, 
stained with uranyl acetate and lead citrate. Examination was performed in a Jeol – 
1200 EX transmission electron microscope (Jeol, Peabody, MA, USA). 
JC-1 metabolic staining and fluorescence microscopy 
Analysis of the metabolic state of the cells was based on the specific characteristics of 
JC-1 dye, that exhibit a potential-dependent mitochondrial accumulation, indicated by 
a fluorescent emission shift from green (~525nm) to red (~595 nm). Cells were grown 
to 70% confluence, incubated for 15 min in growing medium containing 10 µg/ml JC-
1. Cells were then washed to remove excess of JC-1 and imaged with a 488 nm laser 
for excitation using a LSM510 Zeiss confocal microscope. Red/green ratios were 
calculated from the relative red and green intensities. For dual visualization of 
mitochondria and microtubules, cells were first incubated in 20 nM 
tetramethylrhodamine methyl ester (TMRM; Life Technologies) for 60 min at room 
temperature. After rinsing, cells were incubated in 250 nM TubulinTracker Green (Life 
Technologies) for 30 min at 37°C, then rinsed and placed in recording HBSS for 
fluorescence imaging with standard TRITC and FITC filters. 
Mitochondrial motility 
Cell imaging. For live imaging of the mitochondria, cells were plated on MatTek dishes 
(MatTek, Ashland, MA) at a concentration of 25,000 cells/plate and transfected with 
CellLight Mitochondria GFP, BacMam 2.0 (Life Technologies, Grand Island, NY) at a 
concentration of 40 particles per cell (Kandel, Chou et al. 2015). Cells were imaged the 
following day in Recording HBSS (HBSS pH 7.4 with 1.3 mmol/L CaCl2, 0.9 mmol/L 
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MgCl2, 2 mmol/L glutamine, 0.1 g/L heparin, 5.6 mmol/L glucose, and 1% FBS). Cells 
were imaged using a QImaging QIClick camera (QImaging, Surrey, BC, Canada) (1 × 1 
binning, 1392 × 1040 pixels) attached to Olympus IX70 microscope (Olympus, 
Melville, NY) with an Olympus 40x oil immersion objective lens (Olympus) and 
Photofluor light source (89 North, Burlington, VT) (Bonekamp, Islinger et al. 2013).  
Computer control of the microscope was facilitated by LUDL programmable filter 
wheels, shutters, and focus control (LUDL Electronic Products, Hawthorne, NY), and 
images were collected using IPL 3.7 software (BD, Rockville, MD). For each 
experiment, cells were visualized using a standard FITC filter, and isolated cells with 
well-resolved mitochondria were selected. Cells were imaged for 5 min every 
3 seconds.  
Mitochondrial motility measurements. We preprocessed raw image files in ImageJ as 
previously described (Kandel, Chou et al. 2015). Supplemental Video S1 shows a raw 
image sequence of a control cell and Supplemental Video S2 shows the same video 
after pre-processing in ImageJ. Videos were analyzed by a custom Matlab script 
previously described (Kandel, Chou et al. 2015) which was designed to track the 
movement of individual mitochondria. Net distances traveled by mitochondria were 
calculated using stored centroid locations from each frame. The scripts and 
instructions of our algorithm are included online on Github 
(www.github.com/kandelj/MitoSPT), a freely available software-sharing repository, 
and are intended for public use with proper citation.  
We subjected our analyses to the same restrictions as in our previous work in order to 
maximize our signal-to-noise ratio (SNR). Only objects measuring between 20 and 500 
pixels (~0.5 to ~13 μm2 with our microscope's resolution) and lasting four or more 
consecutive frames (≥9 s) were considered. Sampling frequency was 3 s since more 
frequent sampling increases noise, but less frequent sampling increases the probability 
of missing true signal. 
Statistics. The Matlab function “normal parameter estimates” (normfit) gave the mean 
and standard deviation of the normal distribution best fitting the distribution of logs of 
net distances. This information is used together with the “normal probability density 
function” from Matlab (normpdf) to plot the probability density functions for each 
mitochondrial population. P-values comparing log distributions were computed using 
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the rank-sum test (ranksum function in Matlab). Since acceptance or rejection of the 
null hypothesis based on P-value is by definition affected by dataset sizes, we simply 
report the P-values instead of establishing a threshold for significance when comparing 
our large datasets. 
Oxygen consumption measurement in human fibroblasts  
The mitochondrial oxygen consumption rate (OCR) was measured in human fibroblast 
cells using the Seahorse XF24 Instrument (Seahorse Bioscience, Billerica, MD).  Forty 
eight hours prior to the analysis, both wild-type control and patient fibroblast cells were 
plated on XF-24 plates at 20,000 cells per well and grown in DMEM which contained 
25 mM glucose, 10% FBS and 1% MEM Non-Essential amino acid at 37°C with 5% 
CO2. Immediately before the analysis, the culture medium was replaced by unbuffered 
DMEM XF Base medium (Seahorse Bioscience) at pH 7.4 supplemented with 5 mM 
glucose, 2 mMGlutaMAX and 1 mM sodium pyruvate, and the plates were incubated 
at 37°C in a CO2-free incubator for 15 min. The mitochondrial respiration was 
measured under four conditions: (1) basal conditions, and after the addition of (2) 1.25 
µM oligomycin,  (3) 0.2 µM of the uncoupler, carbonyl cyanide (trifluoromethoxy) 
phenylhydrazone (FCCP) and (4) 1 µM of rotenone together with 1.8 µM antimycin A. 
The drugs were added in the order described above.  Each condition involved three 
cycles of mixing (150 s), waiting (120 s), and measuring (210 s). This series was 
repeated following each injection. 
Results  
Clinical features 
Family A 
Patient A-IV.3 (Fig. 1A) was the first child to first cousin parents of Arab descent.  He 
was born after an uneventful pregnancy via normal delivery. He showed moderate delay 
in motor and speech development from early on. At 19 months, one week after a 
vesicular rash consistent with varicella infection, he developed acute perioral twitching 
resembling myokymia, followed by involuntary myoclonic jerks of the right hand, 
which did not correspond to ictal or interictal electroencephalographic changes, and 
were unresponsive valproic acid, clonazepam and primidone. At Sheba Medical Center, 
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he was alert although hypotonic with constant perioral and right hand, asynchronous, 
continuous myoclonic jerks. Awake EEG showed generalized slowing with intermittent 
spikes asynchronous to the jerks. Further evaluation included elevated inflammatory 
indices (CRP 112 mg/l; normal reference, <3.0), but all other vasculitic indices were 
normal. Blood was positive for a shell vial CMV assay. CSF was acellular with normal 
glucose and protein levels. Brain MRI showed numerous bilateral sub-cortical 
hyperintense white matter foci on FLAIR sequences (Fig. 2A). A preliminary diagnosis 
of acute disseminated encephalomyelitis (ADEM) was made. After showing no 
response to a course of IVIG (2 gr/kg), pulse steroid treatment (30 mg/kg/day for 3 
days) was given, which resulted in a transient remission of myoclonus that reappeared 
a week later, becoming more aggressive and evolving into tonic-clonic status 
epilepticus resistant to a variety of anticonvulsant drugs which partially remitted only 
after high doze midazolam treatment under anesthesia.  
EEG at that point showed a pattern of multiple independent spike foci (MISF). Single-
photon emission computed tomography (SPECT) demonstrated focal increased uptake 
in the inferior left tempo-parietal area, suspected to be the epileptogenic focus while  
repeat MRI showed general atrophy more dominant on the right. Brain biopsy from the 
right occipital region demonstrated mild perivascular lymphocytic infiltrates, fibrillary 
gliosis involving mainly the grey matter and microglia activation with no evidence for 
microglial nodules or viral inclusions (Fig. 2B).  On electron microscopy inclusion 
bodies in  neuronal processes were detected (Fig. 2B). PCR analysis from  tissue biopsy 
was positive for CMV and negative for all other viruses looked at. Other clinical 
information arenin Table 2. The biopsy was interpreted as consistent with non-specific 
chronic encephalitis. The diagnostic hypothesis was of bilateral Rasmussen’s 
encephalitis, possibly related to CMV infection. Despite treatment with 5 cycles of 
plasmapheresis and immunoglobulins he continued to deteriorate with loss of all 
developmental milestones and ongoing multifocal myoclonus, and died at the age of 
2.5 years in another center. 
His female cousin (A-IV.10, Fig. 1A) was born at term after an uneventful pregnancy 
and like A-IV-3 showed  mild motor delay before acute onset of disease-related 
symptoms. At 14 months she presented with perioral twitching movements followed by 
myoclonic jerks of the right arm; EEG then was normal. Twitching then evolved within 
several weeks to generalized tonic-clonic seizures and continuous polymyoclonus 
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which persisted despite treatment with valproic acid and clonazepam. Her condition 
remained unchanged for the following 3 months, at which point in addition to the 
myoclonus she developed severe generalized hypotonia and weakness, poor oral intake 
and decreased alertness. In addition, she developed respiratory distress requiring 
intubation and mechanical ventilation.  
Upon admission at Sheba Medical Center, the infant showed evidence of failure to 
thrive (FTT) and had multifocal myoclonus with intermittent generalized tonic seizures. 
Interictal EEG showed multifocal polyspike wave activity. Blood PCR for CMV 
showed 200 copies/mL. CSF was acellular with mildly elevated protein concentration 
(66 mg/dl)  and normal glucose and lactate; PCR assays were negative for several 
viruses including CMV. Brain MRI showed generalized atrophy without focal changes 
(Fig. 2A). Brain biopsy showed non-specific changes of increased astrocytosis, 
activation of microglia, and perivascular cuffing by lymphocytes (Fig. 2B). All 
lymphocytes stained positive for CD3 (T cells) and negative for CD20 (B cells). CMV 
PCR was negative and no viral inclusions were reported. She continued to deteriorate 
and succumbed at the age of 18 months. 
Family B 
Patient B-V.4 (Fig. 1B) was the fourth child to consanguineous (first cousin) parents, 
born after an uneventful pregnancy via Cesarean section. At 2.5 months of age he began 
experiencing clonic-like episodes that involved each limb separately intermixed with  
generalized myoclonic jerks. On examination he was extremely spastic with very brisk 
tendon joint reflexes up to sustained clonus. EEG was considered normal while brain 
CT and MRI showed mild frontal atrophy. Myoclonus responded transiently to 
phenobarbital treatment and a provisional diagnosis of hyperekplexia was made. The 
clonic/myoclonic episodes relapsed and partially responded to Valproic acid; he, 
however, had myoclonic status epilepticus at 22 months of age. Despite aggressive 
intravenous treatment only partial remission was achieved and he continued to have 
right-sided facial and body jerking consistent with epilepsia partialis continua (EPC) 
unresponsive to variety of anticonvulsant drugs. In the meantime he also showed 
moderate developmental delay (able to sit at 12 months, able to stand at 18 months; 
unable to walk; and with significant speech delay). At 3 years, his seizures progressed 
and was in and out of status epilepticus in a local hospital ICU. He gradullay 
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deteriorated, lost independent breathing, and died during a septic episode in the 
hospital. 
His brother (B-V.5 in Fig. 1B), the youngest of five siblings, was born after an 
uneventful Cesarean section. In the first year of life he showed mild developmental 
delay with mixed tone but no seizures were noticed. At 13 months of age he developed 
episodes of facial twitching with occasional upper limb myoclonus without loss of 
consciousness, partially responsive to anticonvulsants; a month later he went into 
myoclonic status epilepticus accompanied by lethargy. EEG showed normal 
background activity and occasional bilateral independent spikes. The myoclonic 
episodes responded to combined anti-epileptic drug (AED) therapy, but he remained 
lethargic and rapidly lost developmental milestones and became severely spastic, and 
later required tube feeding due to poor swallowing ability. He died suddenly during 
night sleep at home at 17 months of age.   
Repeat MRIs had shown only mild progressive cortical atrophy. No further workup was 
performed, but DNA was preserved and analyzed after their death given their clinical 
similarities to the prior patients. 
Family C 
Patient C-IV.3 was the third child to consanguineous (first cousin) parents of Arab-
Muslim descent. She was born following uneventful pregnancy and delivery. At 40 
days, an increased startle response was noticed, followed by recurrent episodes of 
generalized myoclonic jerks of various length with normal interictal EEG. At 4 months, 
she was found cyanotic and apneic in bed, but responded to cardiopulmonary 
ressucitation. From 7 months, she had recurrent generalized tonic clonic seizures, with 
occasional episodes of generalized status epilepticus. Seizures were intractable to 
various AED's and were intermixed with very frequent polymyoclonuc. Despite the 
intractable seizures, her developmental milestones were only moderately delayed with 
independent walking at 18 months and ability to say a few words at 2 years. At 28 
months, following a prolonged status epilepticus, she abruptly lost all milestones but 
was able to maintain eye contact. She was still fed by mouth and breathed 
independently. She died at home at 5 years of age after a pulmonary infection. 
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Her younger sister (patient C-IV.4) was also born following normal pregnancy and 
delivery. Mild myoclonic jerks were noticed by the mother at 1 month of age, however 
became continuous and overt at 7 months of age. In addition, she had several prolonged 
episodes of generalized myoclonus several weeks apart, with normal interictal EEG. At 
7 months, she developed generalized tonic-clonic status epilepticus which subquently 
remitted after IV medication. Recurrent episodes of AED-unresponsive seizures 
ensued. Despite the recurrent seizures, she acquired developmental milestones, sitting 
at 6 months, crawling at 8 months and walking independently at 15 months, and could 
say a few words and understood simple commands. At 20 months, she had a prolonged 
status epilepticus requiring hospitalization, and she subsequently lost most of her  
developmental milestones. Initial evaluation included a brain MRI, which was 
considered normal, along with other investigations (Table 2). Currently, at 4 years of 
age, she is alert and maintains good eye contact, however has no gross motor abilities. 
She has continuous facial twitching, tongue fasciculations, almost continious 
(right>left) arm clonic movements consistent with epilepsia partialis continua (EPC), 
she shows axial hypotonia with severe limb spasticity with evolving joint contractures 
with +4 DTR's and a positive Babinski sign. 
Identification of loss of function variant in TRAK1  
Exome sequencing performed for individuals A-IV.3, A-IV.10 and their parent (A-
III.2) from family A (Fig 1A) identified 3 rare variants compatible with autosomal 
recessive inheritance. One was c.287-2A>C, a homozygous splice acceptor site variant 
in intron 3 of the TRAK1 gene (NM_001042646). The same variant was found in the 
affected individuals in family B (B-V.4 and B-V.5) and C (C-IV.3 and C-IV.4). To 
further confirm the disease segregation of the c.287-2A>C variant, we performed 
Sanger sequencing of all available DNA. Complete segregation of the variant to disease 
was found in the three families in this report (Fig. 3A).  
The variant was not found in Exome Aggregation Consortium (ExAC) database, 
Cambridge, MA (http://exac.broadinstitute.org) [accessed 08/2016] nor in ClinVar 
(Landrum, Lee et al. 2016) (http://www.ncbi.nlm.nih.gov/clinvar/) nor in our in-house 
database (Gahl, Wise et al. 2015). The variant is in a highly conserved nucleotide and 
predicted to affect splicing. To delineate the effect of the variant on TRAK1 mRNA, we 
generated cDNA from skin fibroblast from two affected individuals (A-IV.3 and A-
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IV.10) and unaffected control. A PCR primer set was designed to amplify flanking  
exons 1 and 4 with expected product size of 585 base pairs (bp). Electrophoresis in 3% 
agarose gel of RT–PCR products revealed that the c.287-2A>C variant induces the 
formation of two mutant isoforms (Fig. 3B) that are less than 585 bp. Direct sequencing 
of these shortened fragments (Fig. 3C) demonstrated a deletion of the entire exon 3 
(NM_001042646.2: c.287_363del) in one fragment and a deletion of the first 16 bp of 
exon 3 in the other (NM_001042646.2: c.287_302del). This 16 bp deletion is likely 
created by the activation another potential cryptic acceptor splice site within exon 3, 
located 16 bp downstream of the original acceptor site. Both exon skipping or the 
deletion of 16 bp are predicted to shift the frame and create premature termination 
codons, NM_001042646: p.Leu96Glnfs*46 and p.Leu96Glnfs*5, respectively (Fig. 
3D). We checked the effect of splicing on all the predominant isoforms and found 
similar splicing pattern in all of them (data not shown). Since the variant results in the 
formation of early termination codon, we predicted nonsense mediated decay of the 
affected transcripts. As expected, analysis of two predominant transcripts of TRAK1 in 
the fibroblasts from patients compared to control, show very little expression of 
NM_001042646.2 (0.02% in A-IV.3 and 0.03% in A-IV.10) and no detectable 
expression of NM_014965.4 in both patients (Fig. 3E). Consistent with this finding, 
analysis of TRAK1 protein expression using a polyclonal antibody specific to all the 
isoforms showed severely reduced expression in both patients (Fig. 3F), indicating that 
this was a loss of function variant.  
Apart from the mutation in TRAK1 variant, additional variants in two other 
genes were identified by WES, namely SHROOM2 [ChrX(GRCh37):g.9863977G>A; 
NM_001649.3:c.2029G>A; p.Ala677Thr] and ANGPTL3 
[Chr1(GRCh37):g.63063479C>T; NM_014495.3(ANGPTL3):c.242C>T; 
p.Ser81Phe]. Segregation analyses, however, out SHROOM2 and ANGPTL3 as 
possible causative mutations.   
 
Effects of TRAK1 pathogenic variant in mitochondrial function 
Fibroblasts derived from two affected members of family A (A-IV.hyper3 and A-IV.10) 
and normal control subjects were stained using JC-1 mitochondrial membrane potential 
dye. Cells carrying the pathogenic variant in TRAK1 exhibit both irregular patterns of 
mitochondrial scattering in the cell (Fig. 4A, right panels) compared to normal control 
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cells (Fig. 4A, left panels), as well as a reduced metabolic state, reflected by a lower 
red/green ratio (Fig. 4B). In addition, mitochondria extended to the cell periphery in 
control cells, while in patient cells, mitochondria remained clustered around the nucleus 
(Fig. 5A). We then looked at the status of microtubules, which are involved in proper 
mitochondrial localization in cells. Microtubules appeared intact in control as well as 
patient cells, confirming that there was no defect in microtubule structure in any of 
these cells (Fig. 5A).  
Mitochondrial motility  
Consistent with our previous work (Kandel, Chou et al. 2015), net distances traveled 
by mitochondria in control cells (Fig. 5B) followed a log-normal distribution. We found 
that mitochondria in patient cells traveled shorter net distances than control 
mitochondria (Table 2 and Fig. 5C). The geometric mean net distance traveled by 
control mitochondria was 192.6 nm (n=3640 mitochondria from 15 cells); 
Supplemental Video S1 shows representative control mitochondria movement, in 
which case the geometric mean net distance is 206.8 nm. For patient A-IV.3, the 
geometric mean was 160.4 nm (n=2691 mitochondria from 13 cells), giving a p-value 
of 7.96E-10 vs. control using the rank-sum test. A sample cell from this population is 
shown in Supplemental Video S3, with the corresponding processed video given as 
Supplemental Video S4.; the mitochondria in this particular cell traveled a geometric 
mean net distance of 164 nm. Patient A-IV.10 showed an even greater decrease in 
mitochondrial motility than patient A-IV.3, with a geometric mean net distance of 142.9 
nm (n=1505 mitochondria from 12 cells). The p-value comparing this population to the 
control mitochondria was 2.25E-16. Supplemental Video S5 shows a sample cell from 
patient A-IV.10, and Supplemental Video S6 shows the corresponding processed video 
used for analysis; the mitochondria in this cell traveled a geometric mean net distance 
of 153.8 nm over the course of the 5 minutes recorded.  
Loss of TRAK1 function does not disrupt peroxisomal distribution and motility  
Mitochondria and peroxisomes exhibit a close functional interplay and cooperate 
metabolically (Schrader, Costello et al. 2015). Furthermore, Miro1 was also detected 
on peroxisomes (Costello, Castro, 2015, submitted). We analyzed the distribution of 
peroxisomes in control and patient fibroblasts (Fig. S1). In contrast to mitochondria, 
which cluster around the nucleus in patient cells, peroxisomal distribution was similar 
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to that of control cells (Fig. S1A). Peroxisomes were uniformly distributed within the 
cytoplasm and reached the cell periphery. Like mitochondria, peroxisomes bind to and 
move along microtubules in mammalian cells (Schrader, King et al. 2000). To analyze 
peroxisome motility, control and patient fibroblasts were transfected with a GFP fusion 
protein bearing a peroxisomal targeting signal (GFP-SKL). GFP-SKL localised 
exclusively to peroxisomes, and no alterations in peroxisome distribution were 
observed in live cells, confirming the immunofluorescence results (not shown). 
Analysis of peroxisome motility revealed no differences in long range, microtubule-
dependent motions between controls and patient fibroblasts (Fig. S1B). Only a small 
population of peroxisomes moved in a microtubule-dependent manner at a given time 
point, which is consistent with published data (Rapp, Saffrich et al. 1996, Wiemer, 
Wenzel et al. 1997, Schrader, King et al. 2000). These observations further confirm the 
integrity of the microtubule network in patient cells and reveal that a loss of TRAK1 
function appears to specifically affect mitochondrial distribution and motility in 
fibroblasts.  
Oxygen consumption measurement in human fibroblasts  
To understand the metabolic effects in the mitochondria due to the TRAK1 deficiency, 
we used the Seahorse analyzer to measure the cellular oxygen consumption rate (OCR). 
Our results indicated that the maximal respiration capacity in fibroblast cells harboring 
the  pathogenic variant in TRAK1 are significantly decreased compared to normal 
fibroblasts shown in Figure 6. 
Discussion 
This is the first report of TRAK1 pathogenic variant in patients with 
neurodevelopmental delay, seizures and fatal encephalopathy. Our patients harbor a 
biallelic splicing variant in the early coding exon of TRAK1 that results in premature 
termination during translation. Furthermore, mRNA analysis showed severely reduced 
level of normal transcripts; aberrant transcripts produced by the mutant isoforms are 
likely degraded through nonsense mediated decay. The predicted truncated protein 
products  do not have the C-terminal domain of TRAK1 that is crucial for its interaction 
with mitochondria, and therefore lose the ability to localize to the mitochondria 
(Webber, Li et al. 2008). This was supported by our western blot results showing 
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severely reduced expression of TRAK1 using an antibody that recognizes the middle 
portion of the protein. Given that affected patients from our cohort come from 
consanguineous background, it is also possible to consider that other deleterious 
variants may contribute to the disease phenotype. In our analysis, we have identified 
ANGPTL3, which was associated with familial hypobetalipoproteinemia, and SHROOM2, 
which has not been associated with human disease. Both candidate genes, however, are 
unlikely, given the fact that they did not segregate with disease by Sanger sequencing.   
Because of a requirement for high energy and calcium buffering during synaptic 
neurotransmission, the proper distribution of mitochondria in neurons is essential 
(Brickley, Pozo et al. 2011). Given the long distances that often separate the neuronal 
soma from its terminus, and the fact that the majority of mitochondria are generated in 
the neuronal body, it would be impractical for neurons to rely on the slow diffusion of 
ATP in order to meet their energy demands.  In mammals, the motors that move 
organelles in an anterograde direction are the kinesins; in particular, the motors of 
mitochondrial axonal transport belong to the kinesin-1 family, encoded by KIF5A, 
KIF5B and KIF5C (Sheng and Cai 2012). The adaptor proteins, TRAK (TRAK1 and 
TRAK2) and MIRO (Saotome, Safiulina et al. 2008, Macaskill, Rinholm et al. 2009, 
Wang and Schwarz 2009), connect the KIF5 motors to the mitochondria. Knockdown 
of TRAK1 in hippocampal neurons led to significant impairment in mitochondrial 
motility and affected both anterograde and retrograde transport (Brickley, Pozo et al. 
2011). TRAK1 is also part of the quaternary mitochondrial trafficking complex together 
with OGT, TRAK2, MIRO, KIF5 (Brickley, Pozo et al. 2011). Using fibroblasts 
derived from patients, we showed that TRAK1 deficiency significantly impaired 
mitochondrial motility; it is possible that the mechanism for mitochondrial movement 
in fibroblasts is similar to that in neurons.  
Cells carrying pathogenic variants in TRAK1 exhibit irregular mitochondrial 
localization in the cell, which is expected considering the role of TRAK1 in 
mitochondrial motility, but they also exhibit mitochondrial dysfunction. This was 
demonstrated by a lower red/green ratio of JC-1 metabolic staining, reflecting an altered 
mitochondrial membrane potential and a reduction in metabolic state, as well as a 
reduction in mitochondrial oxygen consumption. Previous studies showed an 
association between transport defects and altered mitochondrial morphology(Varadi, 
Johnson-Cadwell et al. 2004, Fransson, Ruusala et al. 2006), which is tightly related to 
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its function (Anesti and Scorrano 2006). Another association between motility and 
function is the increase in mitochondrial calcium uptake following blockage of 
mitochondrial motility. These clues and our findings imply the possibility of TRAK1 
involvement in the regulation of mitochondrial function, in addition to its role in 
mitochondrial motility.  
Our patients main clinical features were of paroxysmal events  of two main types: First, 
all presented with polymyoclonus with onset from 1-15 months of age. These 
myoclonic jerks tended  to worsen and become more overt with elapsing time and 
evolved into "multifocal"  Epilepsia partialis continua involving  different body parts. 
The myoclonic jerks were not always accompanied by ictal electroencephalopgraphic 
changes. Second, few months after the myocolonic events, all patients developed GTC 
seizures with high tendency to evolve into generalized tonic clonic status epilepticus 
both resistant to most AED's; status epilepticus events required sedation by anesthetic 
drugs. When generalized tonic clonic seizures started to appear, epileptiform activity in 
the form of multifocal and generalized spike wave were identified on the inter-ictal 
EEG. In addition, all patients which were either hypotonic or initally with normal tone 
developed progressive spasticity. Their developmental course was unique: patients had 
mild to moderate developmental delay in the first 1-2 years of life, but all patients 
rapidly regressed and lost global developmental milestones consistently after an 
episode of generalized status epilepticus. All patient but patient C-IV-4, who is still 
alive although severely handicapped at 5 years of age, died within weeks to months 
after their abrupt regression.  
Dominant mutations in KIF5A, a neuron specific kinesin protein which interacts with 
TRAK1 as its linker protein to mitochondria (Glater, Megeath et al. 2006) has been 
associated with spastic paraplegia type 10 both in its pure and complicated variants with 
onset from early childhood to early adulthood (Reid, Kloos et al. 2002, Goizet, 
Boukhris et al. 2009). The main mechanism considered to cause both progressive 
spasticity and peripheral neuropathy in KIF5A mutated patients and models is related 
to anterograde axonal deficient mitochondrial transport caused by dysfunctional 
KIF5A. It is possible that the spasticity seen in our patients can be explained by 
secondary dysfunction of KIF5A because of its abnormal linking to mitochondria when 
TRAK1 is dysfunctional or to the primary role of TRAK1 in mitochondrial transport in 
axons. Recently, a de novo variant in the cargo binding domain of KIF5A was reported 
 19 
in patients with myoclonic seizures, hypotonia, profound neurodevelopmental delay 
and progressive leukoencephalopathy (Rydzanicz, Jagla et al. 2016). The phenotype is 
consistent with the existing information that more than 75% of conditional Kif5a-KO 
mice undergo seizures and die within 3 weeks (Xia, Roberts et al. 2003). One KIF5A 
patient presented with myoclonus resembling that of our patients and similar to them 
lacked obvious electroencephalographic abnormalities, suggesting either subcortical or 
peripheral myoclonus. 
Another explanation to the progressive spasticity in our patients relates to the role of 
TRAK1 as regulating cargo other than mitochondria. Variants in the mouse orthologue 
of human TRAK1 (hyrt mutant mice) are associated with low levels of γ-aminobutyric 
acid type A (GABAA) receptors, and hence deficiency of GABA-mediated neural 
inhibition, in the CNS of hypertonic mice (Gilbert, Zhang et al. 2006). Histological 
examination and staining with hematoxylin and eosin from CNS samples of the hyrt 
mutant mice revealed oval-shaped inclusion bodies that appeared vesicular in nature 
(as opposed to the typical protein aggregates seen in neurodegenerative diseases). They 
had two layers of membrane and were present in the neuronal processes of the gray 
matter, rather than in the cell bodies. A role of TRAK1 in the regulation of endocytic 
trafficking of the GABAA receptors was then postulated, as a mechanistic explanation 
for motor disinhibition and hypertonicity in the mouse model. 
In fact, all our patients showed progressive spasticity. Although pyramidal signs and 
limb spasticity may develop in mitochondrial disorders usually related to white matter 
involvement, hypotonia is a more common sign. One may speculate that the severe 
spasticity in our patients is at least partially related to the effect of TRAK1 variant on 
the GABAA receptors in the lower motor neurons leading to decreased motor neuron 
inhibition by GABAA as described in hyrt mice (Gilbert, Zhang et al. 2006). Because 
of the profound generalized encephalopathy and epilepsy in our patients, the clinical 
management did not include anti spastic drugs like baclofen (a GABAA agonist). 
Nevertheless, this treatment should be considered when facing a patient with TRAK1 
variant(s) in the future.  
The presenting paroxysmal symptom of our patients was of multifocal myoclonus 
evolving in most to epilepsia partialis continua (EPC). EPC is a condition that may 
develop in patients with inflammatory brain disorder (e.g. Rasmussen's encephalitis) 
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(Kravljanac, Djuric et al. 2013) but would also be consistent with mitochondrial 
disorders (Riquet, Auvin et al. 2008, El Sabbagh, Lebre et al. 2010, Desguerre, Hully 
et al. 2014). Although no good pathophysiological explanation for its development in 
mitochondrial diseases exists, seizures could be related to patchy cellular mitochondrial 
dysfunction either because of heteroplasmy in mitochondrially inherited disorders (as 
in MELAS) or uneven mitochondrial depletion in various neurons (as in POLG1). We 
hypothesize that this type of seizures can result from defective mitochondrial motility 
in neurons related to their length in TRAK1 deficiency. With progression of the 
disorder, the epilepsy became more generalized, accompanied by other neurological 
deficits including developmental delay and after the acute regression to brainstem 
involvement leading to early death. At no point were mitochondrial-related metabolic 
derangements noticed; specifically, there were no elevations of lactate in blood or CSF, 
blood amino acids, or urine organic acids, nor was there evidence for extra CNS 
systemic involvement. This could be explained by the fact that the respiratory chain 
pathway inside the mitochondria was only mildly affected by pathogenic TRAK1 
variants but the "supply" of these mildly dysfunctional mitochondria to the active axons 
caused much greater "localized" energy deficits; normal mitochondrial motility may 
also be more important for neurons than for other cells. The absence of systemic 
involvement or a biochemical metabolic signature necessitates direct genetic testing in 
patients with similar neurologic phenotypes. 
The direct association between TRAK1 and seizure disorder was raised by Chioza et al 
(Chioza, Aicardi et al. 2009). in a study looking at genome wide single nucleotide 
polymorphism-based high density linkage in 41 pedigree families with at least 2 
affected members with childhood absence. TRAK1 was demonstrated as the strongest 
candidate within a susceptibility locus on chromosome 3p23-p14. 
An additional explanation for the role of TRAK1 in epilepsy besides its effect on 
mitochondrial functions can perhaps be related to its association with the intracellular 
loop of GABAA receptor b3 subunits (Stephenson 2014). Homozygous mutations  in 
the GABAA receptor b3 subunits were found to be related to familial absence epilepsy 
and De novo mutations to severe early epileptic encephalopathies while this gene knock 
out mice is used as a model for absence epilepsy; all suggesting that dysfunctional 
GABAa B3 subunit related to abnormal trak1 guidance may lead to an epileptic 
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phenotype (DeLorey, Handforth et al. 1998, Tanaka, Olsen et al. 2008, Epi, Epilepsy 
Phenome/Genome et al. 2013).  
In summary, we describe for the first time a devastating human disorder associated with 
a null allele in the TRAK1 gene and subsequent dysfunction of mitochondrial 
trafficking. The complex disease manifestations may be explained by two separate- or 
perhaps combined- mechanisms, of mitochondrial and gabaergic receptor dysfunction. 
While using a fibroblast model we managed to prove the mitochondrial dysfunction, 
further investigations into the gene's product and its defects in various models may lead 
to better understanding of the complicated underlying pathology, and perhaps pave the 
path for mechanism-directed interventions.  
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Figures and Figure legends 
 
Figure 1. Pedigrees of patients with pathogenic TRAK1 variants. Patients in 
Families A (A), B (B) and C (C) are depicted. Open symbols represent unaffected 
individuals, filled symbols designate affected individuals and are homozygous for the 
splicing variant. N/A, not available. Symbols with small circles within designate 
carrier status for the splicing variant.   
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Figure 2. Neuroimaging and brain biopsy studies. 
(A) Brain magnetic resonance imaging (MRI) studies of affected cousins from Family 
A: T2 FLAIR axial image of patient A-IV.3 at the level of the lateral ventricles 
demonstrating abnormal signal of the periventricular white matter (WM) (i); T2 axial 
image of patient A-IV.3 at the same level demonstrates grey and white matter atrophy 
accompanied by signal abnormality of the periventricular WM (ii); ADC calculation of 
the image of patient A-IV.10, consistent with diffusion restriction suggesting metabolic 
compromise (iii); DWI sequence at the same level shows abnormal cortical signal 
bilaterally in the occipital lobes (iv). (B) Brain biopsy histology of patients A-IV.3 and 
A-IV.10: H&E staining revealed round-oval shaped structures seen in the neuropil of 
the grey matter (arrows). Magnification, X600. (C) Transmission electron micrograph 
(IV.3) in (i) shows the distribution of mitochondria at the periphery of the cell; (ii) is at 
a higher magnification, demonstrating clusters of the mitochondria (arrows) observed 
at the cell periphery. Electron micrograph in (iii) indicates an inclusion body (arrow) in 
a neuronal process. High magnification of the inclusion body (iv) indicates that the 
inclusion consists of aggregates of vesicles.  
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Figure 3. 
Molecular analyses of TRAK1 variant in patients.  
(A) Sample chromatogram showing the Sanger confirmation of the variant in the 
families (wild type, heterozygous, and homozygous) (B) RT–PCR products obtained 
with primer pairs (flanking exon 3) for amplification of the mRNA from two affected 
individuals (A-IV.3 and A-IV.10) and one control. The results indicate two abnormal 
cDNA fragments in  affected individuals compared to control: a 16-base pair deleted 
(Mutant isoform A) and 77-base pair deleted (Mutant isoform B). (C) In comparison to 
control (upper panel), sequencing of affected individual's aberrant transcripts shows 
lack of the first 16 base pair of TRAK1 exon 3 (middle panel) and entire exon 3 (lower 
panel). (D) Schematic diagram of splicing defect, showing the formation of two 
different mutant transcripts (Mutant Isoform A and Mutant Isoform B). (E) 
Significantly reduced expression of Transcript 1 (NM_001042646) in patients, 
comparison to control. Results were normalized with the expression of a housekeeping 
gene, POLR2A. Transcript 2 (NM_014965.4) was undetectable in both A-IV.3 and A-
IV.10. (F) Western blot results showing significantly reduced or no expression of 
TRAK1 in both patients in comparison to control. Beta actin (ACTB) was used as 
loading control. Lanes 1 to 7 represent : 1, ladder; 2 and 3; contro; 4 and 5, A-IV-3; 6 
and 7, A-IV-10. 
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Figure 4. JC-1 metabolic staining.   
(A) Images from fibroblasts of affected individuals (A-IV-3 and A-IV-10) and 
unaffected control incubated with JC-1 dye. A fluorescent shift from green to red 
indicates a potential-dependent mitochondrial accumulation. (B) Red/green ratios were 
calculated from the relative red and green intensities and are shown as a graph below 
the images.  
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Figure 5. Analysis of mitochondrial  movement in fibroblasts.  
(A) Microtubule staining. Fibroblasts from control and different patients (A-IV.3 and 
A-IV.10) are stained with TubulinTracker (green) and TMRM (red). Scale bar is 50 
µm. (B-D) Images depicting mitochondrial movement. (B) Image of a sample control 
cell before and after ImageJ processing. Scale bar is 20 µm. (C) Path lengths of all 
mitochondrial centroids in this cell. Box indicates inset region. Inset: path length of one 
particular mitochondrion, with start and finish points indicated. This mitochondrion 
traveled a total distance of 9.52 µm and a net distance of 2.47 µm. (D) Probability 
density plots of net distances traveled by control and patient mitochondria. 
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Figure 6. Oxygen consumption rates in fibroblasts. 
Cellular oxygen consumption rates (OCR) for fibroblast cell lines from wild-type and 
TRAK1 c.287-2A>C patient (A-IV.3) was measured by XF24 extracellular flux 
analysis. Oligomycin (1.25µM), carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP, 0.2µM), and antimycin A (1.8µM) together with rotenone 
(1µM) were injected after 20, 50 and 80 minutes respectively. (n=4 plates; *P 
value<0.05). 
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Table 1 – Demographic, clinical and histopathological characteristics of patients 
with TRAK1-related encephalopathy. 
 
Patient 1 
(A-IV.3) 
2 
(A-
IV.10) 
3 
(B-V.4) 
4 
(B-V.5) 
5 
(C-IV.3) 
6 
(C-IV.4) 
Gender M F M M F F 
Consangu
inity 
Yes Yes Yes Yes Yes Yes 
Age of 
onset 
(months) 
19 14 2.5 13 1.5 1 
Presentin
g 
symptom
s 
Perioral 
myoclon
us 
followed 
by 
myocloni
c hand 
jerks. 
Perioral 
myoclon
us 
followed 
by 
myoclon
ic 
unilatera
l upper 
limb 
coarse 
myoclon
us  
Multifoc
al and 
generaliz
ed 
myoclon
us  
Facial 
myoclon
us 
followed 
by 
bilateral 
independ
ent upper 
limb 
myoclon
us  
Exaggerat
ed startle 
response 
and 
recurrent 
episodes 
of 
generalize
d 
myocloni
c jerks. 
Mild 
myoclonic 
jerks 
evolving 
into 
episodes of 
prolonged 
generalized 
myoclonus. 
Develop
mental 
delay 
until 
rapid 
regressio
n  
 + +   ++ + + Normal 
Neurologi
cal signs  
Alert, 
hypotoni
a 
evolving 
to 
spasticity
, constant 
perioral 
and 
upper 
limb 
myoclon
us. 
Alert, 
truncal 
hypotoni
a and 
limb 
spasticit
y, 
swallow
ing 
difficulti
es 
Spastic, 
continuo
us 
multifoca
l 
myoclon
us. 
Alert, 
progressi
ve 
spasticity
, 
multifoca
l 
myoclon
us  
swallowi
ng 
difficluti
es   
Multifoca
l 
myoclonu
s, 
progressi
ve 
spasticity, 
poor 
communi
cation 
skills 
Alert, 
multifocal 
myoclonus, 
progressive 
spasticity .  
Course Multifoc
al 
myoclon
us 
evolved 
At 17m 
episodes 
of 
recurren
t GTC 
Generaliz
ed and 
partial 
tonic 
clonic 
At 14 m 
myocloni
c status 
followed 
by rapid 
CPR at 4 
months 
after 
unclear 
apneic 
At 7 
months 
onset of 
GTC 
seizures 
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into GTC 
seizures 
with 
recurrent 
intractabl
e SE 
resistant 
to all 
AEDs, 
steroids, 
IVIG. 
Loss of 
all 
develop
mental 
milestone
s at 2 
years. 
SE with 
rapid 
deteriora
tion and 
loss of 
all 
mileston
es 
requirin
g tube 
feeding 
and few 
weeks 
later 
assisted 
ventilati
on  
seizures 
from 
12m of 
age, 
myocloni
c status 
epileptic
us at 22 
m of age 
followed 
by 
multifoca
l EPC. At 
3 years 
intractabl
e SE and 
loss of all 
develop
mental 
milestone
s. 
deteriorat
ion and 
loss of all 
develop
mental 
milestone
s. 
episode. 
From 7 m 
recurrent 
GTCs and 
episodes 
of SE. At 
28 m 
rapid 
deteriorati
on 
following 
GTC SE.  
and 
episodes of 
myoclonic 
status and 
GTC 
status. 
Rapid 
regression 
at 20 m 
after 
generalized 
SE.  
 
Brain 
MRI 
Numerou
s bilateral 
subcortic
al white 
matter 
foci. 
Second 
MRI 
showed 
generaliz
ed 
atrophy. 
Generali
zed 
atrophy. 
Mild 
frontal 
atrophy. 
N/A N/A Considered 
normal. 
Brain 
biopsy 
Mild 
perivascu
lar 
lymphoc
ytic 
infiltrates
, 
fibrillary 
gliosis, 
and 
activatio
n of 
microglia
. EM: 
inclusion 
body in a 
Increase
d 
astrocyt
osis, 
activatio
n of 
microgli
a, 
perivasc
ular 
cuffing 
by 
lymphoc
ytes. 
N/A N/A N/A N/A 
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neuronal 
process. 
Additiona
l 
laborator
y 
investigat
ion 
Blood: 
elevated 
CRP, 
positive 
CMV 
shell vial 
assay. 
Normal 
metaboli
c screen 
(blood 
lactate, 
pyruvate, 
ammonia
, liver 
enzymes 
and 
amino 
acids 
profile, 
urine 
organic 
acids 
profiles).  
CSF PCR 
was 
negative 
for an 
array of 
viruses 
including 
CMV. 
Blood: 
positive 
CMV 
shell 
vial 
assay. 
Normal 
metaboli
c screen. 
CSF: 
Negativ
e PCR 
for 
viruses. 
Blood: 
Normal 
metaboli
c screen 
(serum 
lactate, 
ammonia 
and 
blood 
amino 
acids and 
urine 
organic 
acids). 
Blood: 
Normal 
metaboli
c screen 
(serum 
lactate, 
ammonia 
and 
blood 
amino 
acids and 
urine 
organic 
acids). 
 Blood: 
Normal 
metabolic 
screen 
(plasma, 
urine and 
CSF amino 
acid 
profiles; 
urine 
organic 
acids 
profile, 
sulfite 
levels, 
creatinine 
and 
guandinoac
etate). CSF 
lactate 
levels and 
skin biopsy 
for NCL 
were 
normal. 
Age of 
death 
(months) 
30 18 40 17 60 alive 
 
AED, anti-epileptic drugs. CPR, cardiopulmonary resuscitation. EM, electron 
microscopy. EPC, epilepsia partialis continua. GTC, generalized tonic-clonic seizure. 
IVIG, intravenous immunoglobulins. SE, status epilepticus. N/A, not available or not 
relevant. 
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Table 2. Mitochondrial motility parameters and statistics in patient and control 
fibroblasts. 
 n Geo-mean of 
net distances 
(nm) 
p-value vs. 
control 
p-value vs. 
Patient A-1 
Control 3640 
mitochondria 
(15 cells) 
192.6 X X 
Patient A-IV.3 2691 
mitochondria 
(13 cells) 
160.4 7.96E-10 X 
Patient A-
IV.10 
1505 
mitochondria 
(12 cells) 
142.9 2.25E-16 0.0012 
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Supplementary Figure 1 (Fig S1). Distribution and motility of peroxisomes in 
control and patient fibroblasts.  
(A) Cells were processed for immunofluorescence and stained with anti-Pex14 
(green ; peroxisomal membrane marker) and anti-TOM20 (red ; mitochondrial outer 
membrane) antibodies. Peroxisomes are uniformly distributed in control and patient 
cells reaching the cell periphery. Representative images depicting organelle distance 
from the nucleus to the cell periphery. Bar, 20 μm. (B) Analysis of peroxisome 
motility in control and patient cells expressing GFP-SKL. Each data point represents 
the percentage of microtubule (MT)-dependent motility for one cell (MT motility > 
0.24µm/s). No significant differences were observed between control (2.75 ± 0.22) 
and patient fibroblasts (2.47 ± 0.17) (two-tail unpaired t-test).  
